Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
Non-Pharmacologic Treatments for VasomotorSymptoms Associated with Menopause Management Briefs eBrief-no117 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no117 -- Health Services Research & Development Management eBrief no. 117 » Issue 117 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Report: Non-Pharmacologic Treatments (...) for VasomotorSymptoms Associated with MenopauseVasomotorsymptoms (VMS), which include hot flashes and night sweats, are the most common symptoms reported during the menopausal transition. VMS symptoms are experienced by as many as 80% of women with a mean age of onset of 51 years, and can last more than seven years. VMS can lead to increased healthcare encounters for symptom relief and reductions in quality of life. The degree to which VMS are bothersome is determined not only by how frequently
Nonhormonal management of menopause-associated vasomotorsymptoms: 2015 position statement of The North American Menopause Society Copyright @ 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. POSITION STATEMENT Nonhormonal management of menopause-associated vasomotorsymptoms: 2015 position statement of The North American Menopause Society Abstract Objective: To update and expand The North American Menopause Society’s evidence-based position (...) on nonhormonal management of menopause-associated vasomotorsymptoms (VMS), previously a portion of the position statement on the management of VMS. Methods: NAMS enlisted clinical and research experts in the field and a reference librarian to identify and review available evidence. Five different electronic search engines were used to cull relevant literature. Using the literature, experts created a document for final approval by the NAMS Board of Trustees. Results: Nonhormonal management of VMS
Exercise for vasomotormenopausalsymptoms. Evidence suggests that many perimenopausal and early postmenopausal women will experience menopausalsymptoms; hot flushes are the most common. Symptoms caused by fluctuating levels of oestrogen may be alleviated by hormone therapy (HT), but a marked global decline in its use has resulted from concerns about the risks and benefits of HT. Consequently, many women are seeking alternatives. As large numbers of women are choosing not to take HT (...) , it is increasingly important to identify evidence-based lifestyle modifications that have the potential to reduce vasomotormenopausal symptoms.To examine the effectiveness of any type of exercise intervention in the management of vasomotorsymptoms in symptomatic perimenopausal and postmenopausal women.Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials (RCTs): Cochrane Menstrual Disorders and Subfertility Group Specialised Trials Register
Managing Menopause Chapter 4 VasomotorSymptoms Managing Menopause Chapter 4 VasomotorSymptoms - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S31–S34 Managing Menopause Chapter 4 VasomotorSymptoms DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. VMS affect 60% to 80% of women entering menopause. 1 Hot flashes are common (...) in the perimenopausal transition, when ovarian activity may be intermittent, and they have also been documented during the luteal and menstrual phases of the cycle in women with premenstrual dysphoric disorder. 2 After menopause, it is important to be alert to atypical features or to a lack of response to effective therapy, which might indicate an alternative cause of the symptoms. The differential diagnosis includes hyperthyroidism, anxiety, panic attack, hypertension, emotional flushing, neurologic flushing
Vasomotor and physical menopausalsymptoms are associated with sleep quality. Sleep disturbance is one of the common complaints in menopause. This study investigated the relationship between menopausalsymptoms and sleep quality in middle-aged women.This cross-sectional observational study involved 634 women aged 44-56 years attending a healthcare center at Kangbuk Samsung Hospitals. Sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI).Multiple linear regression analysis (...) women. Multiple linear regression analysis adjusted for age, BMI, hypertension, diabetes, smoking, marital status, family income, education, employment status, parity, physical activity, depression symptoms, perceived stress and menopausal status showed that higher PSQI score was positively correlated with higher vasomotor(ß = 0.240, P = 0.020)and physical(ß = 0.572, P<0.001) scores.Vasomotor and physical menopausesymptoms was related to poor sleep quality. Effective management strategies aimed
Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotorsymptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). This study determined whether two different formulations of hormone therapy (HT): oral conjugated equine estrogens (o-CEE; 0.45 mg/d, n = 209), transdermal 17β-estradiol (t-E2; 50 μg/d, n = 201) plus cyclic progesterone (Prometrium, 200 mg) or placebo (PBO, n (...) = 243) affected sleep domains in participants of the Kronos Early Estrogen Prevention Study.Participants completed the Pittsburgh Sleep Quality Index at baseline and during the intervention at 6, 18, 36, and 48 months. Global sleep quality and individual sleep domain scores were compared between treatments using analysis of covariance, and correlated with vasomotorsymptom (VMS) scores using Spearman correlation coefficients.Global Pittsburgh Sleep Quality Index scores (mean 6.3; 24% with score >8
Aerobic exercise for vasomotormenopausalsymptoms: A cost-utility analysis based on the Active Women trial. To compare the cost-utility of two exercise interventions relative to a control group for vasomotormenopausal symptoms.Economic evaluation taking a UK National Health Service and Personal Social Services perspective and a societal perspective.Primary care.Peri- and postmenopausal women who have not used hormone therapy in the past 3 months and experience ≥ 5 episodes of vasomotor (...) exercise social support groups are very likely to be cost-effective in the management of vasomotormenopausalsymptoms.
Improving vasomotorsymptoms; psychological symptoms; and health-related quality of life in peri- or post-menopausal women through yoga: An umbrella systematic review and meta-analysis. Vasomotorsymptoms (VMS), commonly reported during menopausal transition, negatively affect psychological health and health-related quality of life (HRQoL). While hormone therapy is an effective treatment, its use is limited by concerns about possible harms. Thus, many women with VMS seek nonhormonal (...) , nonpharmacologic treatment options. However, evidence to guide clinical recommendations is inconclusive. This study reviewed the effectiveness of yoga, tai chi and qigong on vasomotor, psychological symptoms, and HRQoL in peri- or post-menopausal women.MEDLINE, Cochrane Database of Systematic Reviews, EMBASE, CINAHL and the Allied and Complementary Medicine Database were searched. Researchers identified systematic reviews (SR) or RCTs that evaluated yoga, tai chi, or qigong for vasomotor, psychological
Relationship between vasomotorsymptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone. To characterize the impact of TX-001HR on the relationship between vasomotorsymptom (VMS) improvement and quality of life and sleep.REPLENISH (NCT01942668) was a phase 3, randomized, double-blind, placebo-controlled, multicenter trial, which evaluated four daily doses of 17β-estradiol and progesterone (E2/P4) combined in a single (...) , oral, softgel capsule in postmenopausal women (40-65 years) with a uterus and moderate to severe VMS (≥7/day or ≥50/week). In post hoc analyses, growth models were used to examine relationships between linear changes in VMS frequency and severity over 12 weeks and changes from baseline in the Menopause-Specific Quality of Life (MENQOL; total score and VMS domain) and the Medical Outcomes Study-Sleep (total score, sleep problems indices I and II) questionnaire outcomes at 12 weeks with treatment
Clinical Inquiries: Does exercise relieve vasomotormenopausalsymptoms? No. Exercise doesn't decrease the frequency or severity of vasomotormenopausalsymptoms in perimenopausal and postmenopausal women (strength of recommendation: A, systematic review of randomized controlled trials [RCTs] and consistent RCT).
The role of sleep difficulties in the vasomotormenopausalsymptoms and depressed mood relationships: an international pooled analysis of eight studies in the InterLACE consortium. Many women experience both vasomotormenopausalsymptoms (VMS) and depressed mood at midlife, but little is known regarding the prospective bi-directional relationships between VMS and depressed mood and the role of sleep difficulties in both directions.A pooled analysis was conducted using data from 21 312 women
N-3 Polyunsatured Fatty Acids in Menopausal Transition: A Systematic Review of Depressive and Cognitive Disorders with Accompanying VasomotorSymptoms Depression is one of the most important health problems worldwide. Women are 2.5 times more likely to experience major depression than men. Evidence suggests that some women might experience an increased risk for developing depression during “windows of vulnerability”, i.e., when exposed to intense hormone fluctuations (...) , such as the menopause transition. Indeed, this period is associated with different symptoms, including vasomotor, depressive, and cognitive symptoms, which have all been shown to worsen as women approach menopause. Even though hormonal therapy represents the most effective treatment, side effects have been reported by several studies. Therefore, an increased number of women might prefer the use of alternative medicine for treating menopausalsymptoms. N-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs
A Study of NT-814 in the Treatment of Moderate to Severe Post-menopausalVasomotorSymptoms A Study of NT-814 in the Treatment of Moderate to Severe Post-menopausalVasomotorSymptoms - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. A Study of NT-814 in the Treatment of Moderate to Severe Post-menopausalVasomotorSymptoms (SWITCH-1) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03596762 Recruitment Status : Recruiting
Vasomotorsymptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS). Frequency of vasomotorsymptoms (VMS) in older women and the contributing factors are largely undefined. We measured the frequency of moderate-to-severe vasomotorsymptoms (msVMS) in women ≥60 years of age and examined their characteristics to determine factors that may associate with VMS in older women.A cross-sectional survey was completed using the Menopause Health (...) Questionnaire from the Data Registry on Experiences of Aging, Menopause, and Sexuality. Data were collected from women presenting for menopause consultation to Mayo Clinic, Rochester, MN, from January 1, 2006 to October 7, 2014. We created a binary variable where women were classified as having msVMS bother if they reported "quite a bit" or "extremely" compared with women reporting "not at all" or "a little bit." Women with and without msVMS were evaluated by menopause type, self-rated heath, current
Vegans report less bothersome vasomotor and physical menopausalsymptoms than omnivores. Lifestyle modifications that may reduce menopausalsymptoms have generated much interest. The vegetarian diet has been associated with a lower risk of chronic disease as well as a more healthy hormonal milieu. Our objective in this cross-sectional study was to survey peri- and postmenopausal women to investigate menopausalsymptoms and dietary pattern.Survey distribution in 2015-2016 was aimed at female (...) vegans, vegetarians, and omnivores between the ages of 45 and 80 years, who were active on senior and vegetarian social networking websites and at vegan restaurants and events.We investigated vasomotor and physical symptoms as measured by the Menopause-specific Quality of Life Questionnaire (MENQOL) and dietary pattern classified by animal protein intakes reported in response to food frequency questions.Out of 754 participants who completed the survey, 604 reported they were perimenopausal (n = 121
Exercise for vasomotormenopausalsymptoms. Evidence suggests that many perimenopausal and early postmenopausal women will experience menopausesymptoms, hot flushes being the most common. Symptoms caused by fluctuating levels of oestrogen may be alleviated by HRT but there has been a marked global decline in its use due to concerns about the risks and benefits of HRT; consequently many women are now seeking alternatives. As large numbers of women are choosing not to take HRT (...) , it is increasingly important to identify evidence based lifestyle modification interventions that have potential to reduce vasomotormenopausal symptoms.To examine the effectiveness of any type of exercise intervention in the management of vasomotormenopausalsymptoms (hot flushes and night sweats) in perimenopausal and postmenopausal women.Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials (RCTs): Cochrane Menstrual Disorders and Subfertility
Bioidentical hormones for women with vasomotorsymptoms. Various hormone therapies (HT) are available to treat menopausalvasomotorsymptoms. Bioidentical hormones are chemically identical to those produced by the human body, and several types are well-tested and available on prescription. Many women have opted for bioidentical hormone therapy (BHT) on the assumption that it is safer than other forms of HT. We evaluated the evidence.To determine the effectiveness and safety of bioidentical (...) expected by the Cochrane Collaboration. Our primary outcome was vasomotorsymptoms (hot flushes and night sweats). We evaluated the overall quality of the evidence using Grading of Recommendations Assessment, Development and Evaluation criteria (GRADE).We included 23 RCTs (5779 participants). Most studies (20/23) included only women with moderate to severe hot flushes. All studies compared unopposed 17 beta-estradiol (beta-estradiol) versus placebo or conjugated equine estrogens (CEE). None
Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on VasomotorSymptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials. Conjugated estrogens/bazedoxifene (CE/BZA) reduced menopause-related hot flashes (HFs) in the Selective estrogens, Menopause, And Response to Therapy (SMART) trials. This post hoc pooled analysis of SMART-1 and -2 further characterized effects of CE/BZA on HFs in the overall population and patient subgroups.Data from two randomized (...) average daily HF severity score versus placebo (-1.0, -1.3, -0.3), increased the percentage of women who had a ≥50% (81.2%,87.1%, 50.6%) and ≥75% (62.4%, 74.8%, 26.4%) reduction from baseline in daily frequency of moderate/severe HFs, increased the percentage with ≥50% (38.3%, 58.1%, 11.0%) and ≥75% (24.2%, 38.1%, 5.5%) reductions in average daily HF severity score, and improved MENQOL vasomotor function versus placebo (adjusted mean change-3.08, -3.69, -1.37). CE/BZA was significantly more effective